Vgd-097 - 'link'

Primary endpoint : Time to viral clearance (first of two consecutive negative RT‑PCR results).

Pharmacodynamic (PD) read‑out : ex‑vivo inhibition of RdRp activity in peripheral blood mononuclear cells (PBMCs) demonstrated > 90 % target engagement at 30 mg. Design : Randomized, double‑blind, placebo‑controlled; 2:1 randomization (VGD‑097 30 mg PO qd vs. placebo) for 7 days; N = 48 (32 active, 16 placebo). vgd-097

VGD‑097’s unique binding mode circumvents the cross‑resistance seen with nucleoside analogues and offers a differentiated safety profile (no mitochondrial toxicity, negligible drug‑drug interaction potential). | Patent No. | Territory | Filing Date | Expiration | Claims | |------------|-----------|------------|------------|--------| | WO 2023/124567 | World (PCT) | 12 Jan 2023 | 2038 | Core VGD chemotype, allosteric RdRp binding pocket. | | US 11,987,321 | US | 05 Mar 2024 | 2044 | Specific substitution pattern at C‑4 of pyrimidine core; formulation. | | EP 4,567,891 | EU | 19 Jun 2024 | Primary endpoint : Time to viral clearance (first

Inclusion : Confirmed EBOV infection (RT‑PCR Ct ≤ 30), ≤ 72 h from symptom onset, age 18‑65, no severe hepatic/renal failure. placebo) for 7 days; N = 48 (32 active, 16 placebo)